TNDM Tandem Diabetes Care, Inc.
USHealthcareAs of 2026-07-09 16:00
Why TNDM matters now
Tandem Diabetes Care, Inc. (TNDM) is a US stock in Healthcare. The latest InvestLog snapshot shows $15.37 with +1.39% on the session and $1.05B in market capitalization; recent performance reads 1-month +10.39% and YTD -30.39%.
The latest financial table shown here is Q1 2026, with revenue of $247.2M, net income of $-20.4M, and EPS of $-0.30. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -0.3%.
The latest indexable market news headline is "Does TNDM Stock Still Deserve a Place in Your Portfolio?" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Hold with a median target of $25.50; recent insider activity includes Gasser Elizabeth Anne filing G-Gift. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
7.90
P/S
1.02
EV/EBITDA
-22.31
DCF Value
$-48.81
FCF Yield
-0.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
54.9%
Operating Margin
-7.9%
Net Margin
-9.2%
ROE
-68.3%
ROA
-8.2%
ROIC
-8.4%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $247.2M | $-20.4M | $-0.30 |
| Q4 2025 | $290.4M | $-589.0K | $-0.01 |
| FY 2025 | $1.01B | $-204.7M | $-3.04 |
| Q3 2025 | $249.3M | $-21.2M | $-0.31 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$31.40
Target (Median)
$25.50
Target Range
$21.00 - $55.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Devices
Country
US
Exchange
—
Beta
1.57
Tandem Diabetes Care, Inc., a medical technology firm, specializes in creating, developing, and marketing solutions for individuals globally who manage insulin-dependent diabetes. At the core of its offerings is the t:slim X2 insulin delivery system, an advanced pump platform that integrates the t:slim X2 pump, a disposable 300-unit insulin cartridge, and an infusion set. Tandem further enhances this platform with innovative features like Basal-IQ and Control-IQ technology, as well as G5 Integration capabilities. The company also provides the Tandem Device Updater, enabling users to easily update their pump's software. To facilitate therapy management, Tandem offers t:connect, a web-based application that visually presents diabetes data from the pump, continuous glucose monitoring (CGM) devices, and supported blood glucose meters to patients, their caregivers, and healthcare professionals. Additionally, the Sugarmate mobile application caters specifically to insulin users with diabetes. Tandem has strategic development and commercialization partnerships with leading companies such as Dexcom, Inc. and Abbott Laboratories. Established in 2006 and headquartered in San Diego, California, the company was initially known as Phluid Inc. before rebranding as Tandem Diabetes Care, Inc. in January 2008.